---
title: "Traws Pharma targets 3Q 2026 MHRA resubmission to advance TXM Phase 2a influenza challenge study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290424445.md"
description: "Traws Pharma plans to resubmit an updated toxicology package for tivoxavir marboxil to the UK MHRA in Q3 2026. This filing aims to secure clearance for a Phase 2a seasonal influenza challenge study in healthy volunteers. The update addresses previous MHRA feedback requiring additional preclinical safety work, with a formal agency response expected within 30 days of resubmission."
datetime: "2026-06-22T11:02:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290424445.md)
  - [en](https://longbridge.com/en/news/290424445.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290424445.md)
generator: "portal-rs"
---

# Traws Pharma targets 3Q 2026 MHRA resubmission to advance TXM Phase 2a influenza challenge study

-   Traws Pharma outlined plans to resubmit an updated toxicology package to the UK MHRA in 3Q 2026 for tivoxavir marboxil. \* The filing targets clearance to start a Phase 2a human seasonal influenza challenge study in healthy volunteers; no clinical results have been presented. \* Management expects the updated package to address MHRA requirements, aiming to keep the prophylaxis program moving toward proof-of-concept readouts. \* MHRA feedback prompted additional preclinical safety work; a formal agency response is expected within 30 days of resubmission. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-076058), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)

## Related News & Research

- [TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high](https://longbridge.com/en/news/295974913.md)
- [Parkview LaGrange Hospital hosts drive-up flu shot clinic for area residents](https://longbridge.com/en/news/296244642.md)
- [Co-Diagnostics submits FDA 510(k) for Co-Dx PCR Flu A/B & RSV point-of-care test](https://longbridge.com/en/news/296236160.md)
- [PARKIN: Strong Q2 2026 growth in revenue and profit, led by seasonal cards and developer parking](https://longbridge.com/en/news/296184374.md)
- [S&P 500 Seasonality: Can The First Six Months Predict Performance Of ES Futures?](https://longbridge.com/en/news/296125830.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**